HomeAI · summaries
Storia in 3 fonti
FDA approves Revtorpyk for hormone receptor-positive, HER2-negative breast cancer
The FDA has approved a new targeted therapy combination for the most common subtype of breast cancer.Gedatolisib (Revtorpyk, Celcuity Inc.) plus fulvestrant, with or without palbociclib (Ibrance, Pfizer), was approved for adults with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression during or after
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
FDA approves Revtorpyk for hormone receptor-positive, HER2-negative breast cancer
The FDA has approved a new targeted therapy combination for the most common subtype of breast cancer.Gedatolisib (Revtorpyk, Celcuity Inc.) plus fulvestrant, with or without…
- ·
biopharmadive.com
Celcuity gains FDA approval for closely watched breast cancer drug
Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.
- ·
ynetnews.com
FDA approves breast cancer drug that cut progression risk by 76%
Revtorpyk was approved for women with advanced breast cancer whose disease worsened after previous hormone-based treatments; patients receiving the three-drug combination went a…